Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.
Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.
Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.
Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.
Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.
He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.
Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.
10, rue McMahon
Canada G1R 2J6
- Brisson, HervéEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension 16849+1 email@example.com
Canada G1R 2J6
- Gagné, ChristineEmployeechristine.firstname.lastname@example.org
- Verret, NadiaEmployee+1 418-525-4444, extension email@example.com
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.Journal Article
Asian J Androl, 2021.
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.Journal Article
Can Urol Assoc J, 15 (8), 2021.
F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.Journal Article
Can Urol Assoc J, 15 (10), 2021.
Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.Journal Article
World J Urol, 39 (5), 2021.
Achieving the "trifecta" with open versus minimally invasive partial nephrectomy.Journal Article
World J Urol, 39 (5), 2021.
Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.Journal Article
Br J Cancer, 125 (1), 2021.
A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine.Journal Article
Can Urol Assoc J, 14 (10), 2020.
Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.Journal Article
J Urol, 203 (5), 2020.
Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.Journal Article
Drug Metab Dispos, 48 (2), 2020.
Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.Journal Article
Br J Cancer, 122 (7), 2020.
- Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31
- Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
- Soutien à la recherche, from 2017-07-01 to 2024-06-30
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
- The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression, from 2019-04-01 to 2022-03-30
Recently finished projects
- A Pan-Canadian initiative for the development of biomarker-driven approach to management of prostate cancer, from 2012-04-01 to 2019-12-31